|By Business Wire||
|June 12, 2014 11:25 AM EDT||
Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that NUVISAN Pharma Services (“NUVISAN”) has purchased the ALPHADAS® clinical trials software solution suite for deployment in its Phase I unit located in Neu-Ulm, Germany.
NUVISAN is a fully integrated contract research organization providing clinical development and lab services to the global pharmaceutical industry. For over 30 years, NUVISAN has been assisting their clients in bringing safe and effective pharmaceutical products to market through its complete spectrum of services and the long-standing experience of their staff.
Following a competitive evaluation of commercial software systems and vendors, NUVISAN selected Instem’s ALPHADAS software suite based on its ability to support their clinical development team’s specific needs through flexible configurations, the ability to integrate with other support systems through the unit and for Instem’s rapid deployment services.
In addition to improving processes at their Phase I unit, ALPHADAS will be integrating with NUVISAN’s central lab operations resulting in enhanced quality and consistency while simultaneously improving efficiencies and saving time.
“Following a thorough evaluation of several software solutions, and after visiting with clients of each vendor under consideration, it was clear that ALPHADAS by Instem would not only be replacing our existing system, but was the one solution that would truly be providing us with the platform we need to help our clients succeed,” comments James Dickinson, Head of NUVISAN’s Phase I unit. “In addition to the technology, Instem is a well-respected, stable organization offering NUVISAN true subject matter expertise by staff that have run Phase I labs themselves. Bringing more than just software to us was an essential driver behind our decision and we are looking forward to a quick and efficient rollout of their system.”
Instem’s ALPHADAS software solution suite is a proactive early phase eSource data capture system with comprehensive CTMS capabilities. ALPHADAS is mobile, schedule-driven, and provides real-time bedside or station based direct data capture that virtually eliminates paper-based data.
Access the full news announcement at: http://www.instem.com/news/articles/0614-nuvisan-pharma-services-selects-alphadas.html.
About NUVISAN Pharma Services
NUVISAN Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. NUVISAN delivers services ranging from a single test to fully integrated drug development programs.
More about NUVISAN can be found at www.nuvisan.com.
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum.
To learn more about Instem solutions and its mission, please visit www.instem.com.
Meeting clients at the intersection of investment & return™.
Nov. 26, 2015 03:30 PM EST Reads: 430
Nov. 26, 2015 03:30 PM EST Reads: 513
Nov. 26, 2015 03:15 PM EST Reads: 506
Nov. 26, 2015 02:15 PM EST Reads: 494
Nov. 26, 2015 01:00 PM EST Reads: 385
Nov. 26, 2015 01:00 PM EST Reads: 285
Nov. 26, 2015 12:00 PM EST Reads: 144
Nov. 26, 2015 11:30 AM EST Reads: 114
Nov. 26, 2015 11:00 AM EST Reads: 117
Nov. 26, 2015 11:00 AM EST Reads: 441
Nov. 26, 2015 10:00 AM EST Reads: 283
Nov. 26, 2015 09:45 AM EST Reads: 363
Nov. 26, 2015 09:30 AM EST Reads: 371
Nov. 26, 2015 09:00 AM EST Reads: 474
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
Nov. 26, 2015 08:45 AM EST Reads: 264